Cannabinoid scripts for MS soon

Last year nabiximols (Sativex, Novartis) was registered for patients with muscle spasticity.

However, a change to the Poisons Schedule was required to allow accredited neurologists and rehabilitation physicians to prescribe it from 1 September.

Sponsor Novartis is now working with states and territories to satisfy individual legislative requirements surrounding product quality and safe ‘cold chain’ supply.

A spokesperson said they could not provide an exact date when Sativex would be available.

“There is nothing from a legal perspective to stop it being supplied. We just have to meet the state requirements,” they said.

The company is planning an application to the PBAC for reimbursement of nabiximols, which can cost $500 a month.